secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2026-08-27T13:05:14+00:00
Accession:  0001213900-26-094174
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne reports successful large-animal StereoCED procedures; human studies planned this quarter
--------------------------------------------------------------------------------

- Three large-animal procedures completed using next-gen StereoCED platform at University of Minnesota.
- In two procedures, drug delivery electrodes delivered study agent and recorded intracranial electrophysiological activity from same regions.
- Robotic platform used for trajectory, drilling, and anchor bolt placement; drug delivery and recording successful.
- StereoCED revenue expected in fiscal Q4 2026; human investigational device release planned by end of Q4 2026.
- CEO Dave Rosa cites repeatability and progress toward human investigational clinical studies later this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026094174/0001213900-26-094174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026094174/ea0303530-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-094174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer